Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 784.45

-0.4%

Nov 26 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Biotech Jim	4/29/2015 3:14:36 PM
	Read Replies (2) of 3559

From RBC Capital, this morning's report, with a price target of $490. Thx DH for this. "Potential catalysts for REGN shares • Quarterly results. Expectations will likely come down but still stay high for "beats" and "raises". • Combination Eylea and PDGF-R or ANG2 Phase I data in 2015. • Alirocumab additional Phase III readouts throughout 2015. • Dupilumab Phase II data in 2015. • Pipeline progress and updates from earlier Phase I and Phase II programs, including Phase III 2-year DME data. • Technological innovation leading to new or different approaches to treating various disorders. Risks to our investment thesis • Eylea competitors could post better-than-expected results in wet AMD, RVO, or DME, and Eylea’s sales ramp could be below expectations. • Alirocumab could suffer regulatory, or commercial setbacks. Competition could prove tougher than expected. • Dupilumab and other pipeline candidates could suffer clinical, regulatory, or commercial setbacks or face tougher- than-expected competition. • Expenses could stay high and SNY could stop funding the pipeline." UBet, SNY could stop funding the pipeline. No new data or real insight from this report.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next